VCCBH News


VCCBH Symposium Highlights Early Career Investigators, Innovative Multidisciplinary Research

June 29, 2022 by Jennifer Nachbur and Masayo Koide, Ph.D.

More than 100 in-person and dozens of virtual participants attended the second annual Vermont Center for Cardiovascular and Brain Health (VCCBH) Symposium, held at the University of Vermont’s Davis Center June 2 to 3, 2022. The VCCBH, one of three National Institutes of Health Center of Biomedical Research Excellence-funded programs at UVM, is co-directed by Mary Cushman, M.D., M.Sc., professor and vice chair for emerging researchers in the Department of Medicine, and Mark Nelson, Ph.D., University Distinguished Professor and chair of the Department of Pharmacology.

(Clockwise, from top left): Debora Kamin-Mukaz, Ph.D.; Thomas Heppner, Ph.D., and Gerald Herrerra, Ph.D.; Maddie Hatch, Dr. Cushman, and Rusul Mustafa.

More than 100 in-person and dozens of virtual participants attended the second annual Vermont Center for Cardiovascular and Brain Health (VCCBH) Symposium, held at the University of Vermont’s Davis Center June 2 to 3, 2022. The VCCBH, one of three National Institutes of Health Center of Biomedical Research Excellence (COBRE)-funded programs at UVM, is co-directed by Mary Cushman, M.D., M.Sc., professor and vice chair for emerging researchers in the Department of Medicine, and Mark Nelson, Ph.D., University Distinguished Professor and chair of the Department of Pharmacology.

Established in 2020, the VCCBH aims to improve the understanding of – and optimize treatments for – cardiovascular and neurovascular diseases through research conducted by a multidisciplinary team of clinicians, physician-scientists, basic scientists, statisticians, and other researchers. With the first symposium held virtually in 2021, this was the first time this group of collaborators was able to gather in person since the launch of the VCCBH in 2020. Attendees included UVM faculty and staff, as well as researchers from across the U.S., and world.

During the welcoming ceremonies at the start of the symposium, UVM Larner College of Medicine Dean Richard L. Page, M.D., presented an in-person welcome, and congratulatory remarks from Vermont Senator Patrick Leahy were read to attendees.

Highlights of the two-day event included a “Science Keynote Address,” delivered by Joseph Loscalzo, M.D., chair of medicine and Hersey Professor of the Theory and Practice of Medicine at Brigham & Women’s Hospital and Harvard Medical School. Titled “What is Disease? Defining Pathobiology and Therapeutics in the Era of Big Data,” his presentation focused on the process of developing new therapeutics using databases of protein-protein and structural interactions. The “Diversity and Inclusion Keynote Address” was presented by Michelle Albert, M.D., president-elect of the American Heart Association and professor of medicine and director of the CeNter for the StUdy of AdveRsiTy and CardiovascUlaR DiseasE (NURTURE Center) at the University of California at San Francisco. Titled “Breaking the Shackles: Addressing the Taxonomy of Medical Training to Achieve Health Equity,” her talk discussed the role of structural racism in health inequities, the need for BIPOC individuals to go into medicine, and methods that medical training programs can use to reduce the barriers to success for these individuals.

“Over two days, novel findings – ranging from the molecular level to human epidemiological analysis – brought lively discussions and raised future possible collaborations in the VCCBH research community,” said Masayo Koide, Ph.D., assistant professor of pharmacology and one of the four project directors for the VCCBH.

Additional presentations during the two-day symposium included research talks by VCCBH project directors, pilot grant awardees, and other faculty members. There was an exciting Flash Talk session including rapid fire presentations by seven VCCBH Pipeline Investigators. “Connection Corner” allowed attendees to speak with experts on career development topics.

A panel of five volunteers judged the poster session, including Nels Olson, Ph.D., assistant professor of pathology and laboratory medicine, Neil Zakai, M.D., M.Sc., professor of medicine, Peter Durda, Ph.D., faculty scientist in pathology and laboratory medicine, Maria Bravo, Ph.D., faculty scientist in biochemistry, and Amreen Mughal, Ph.D., assistant professor of pharmacology. Awardees included Maddie Hatch, a doctoral student in chemistry, Swapna Balakrishnan, PT, D.P.T, an interprofessional health sciences doctoral student, Margaret Phillips, Ph.D., a postdoctoral associate in pharmacology, Matthew Caporizzo, Ph.D., assistant professor in molecular physiology and biophysics, and Katharine Cheung, M.D., Ph.D., assistant professor of medicine.

“It is really reflective of our multidisciplinary community that the winners came from three UVM colleges,” said Cushman.

The third annual VCCBH symposium is scheduled for June 2023.

Link to the 2022 VCCBH Symposium agenda



Recent Stories and Publications Featuring VCCBH Members


Target ALS LinkedIn Post Featuring Research by Dr. Kathryn H. Morelli, PhD

Posted January 4, 2025

"ALS is a devastating disease, but researchers like Kathryn H. Morelli, Ph.D., a Target ALS Springboard Fellow and now an assistant professor at the University of Vermont, are driving innovations that bring us closer to effective treatments. Focused on developing RNA-targeted therapies for C9orf72 ALS, one of the most common genetic causes of the disease, Kathy’s work showcases the critical importance of collaboration, cutting-edge tools, and determination..."

Advancing ALS Research with Stem Cell Resources and Targeted Reagents: The Role of Target ALS in the Quest for Effective Treatment

Posted January 4, 2025

"ALS is a devastating neurodegenerative disease, and while there is no cure, ongoing research continues to offer hope for more effective treatments. An individual at the forefront of these efforts is Dr. Kathryn Morelli, an assistant professor in the Department of Neurological Sciences at the University of Vermont’s Larner College of Medicine, whose research aims to address the complex challenges of ALS, building on work she did with her postdoctoral mentor Dr. Gene Yeo. Working closely with Abby Kirch, a PhD student in her lab, Kathy and her team are focused on developing RNA-targeted therapies for ALS, particularly for the C9ORF72 mutation, one of the most common genetic causes of the disease..."

Larner College of Medicine Dean's Newsletter, Accolades and Accomplishments

Posted December 4, 2024

"On November 16, Larner Assistant Professor of Medicine Debora Kamin Mukaz, Ph.D., M.S., moderated a panel on science policy advocacy titled “How can we engage scientists from historically underrepresented backgrounds in policymaking and advocacy?” at the American Heart Association’s Scientific Sessions 2024 conference in Chicago. The panelists were AHA President Keith Churchwell, M.D.; past AHA President Michelle Albert, M.D., M.P.H.; Emelia Benjamin, M.D., Sc.M., associate provost and professor of medicine and epidemiology at Boston University; and Carl Streed, Jr., M.D., M.P.H., associate professor of medicine at Boston University..."

Research on spider brain leads to groundbreaking Alzheimer’s discovery

Posted December 3, 2024

"Neurodegeneration in spider brain leads Vermont neuroscientists to groundbreaking discovery in Alzheimer’s-affected human brains 
Vermont Business Magazine Researchers from Saint Michael’s College and the University of Vermont have made a groundbreaking new discovery that provides a better understanding of how Alzheimer’s disease develops in the human brain..."

Larner College of Medicine Dean's Newsletter, Accolades and Accomplishments

Posted October 23, 2024

"In a recent paper published in Nature Communications titled “Endothelial Piezo1 Channel Mediates Mechano-Feedback Control of Brain Blood Flow,” Osama Harraz, Ph.D., Bloomfield Early Career Professor in Cardiovascular Research and assistant professor of pharmacology at the Robert Larner, M.D. College of Medicine, and his team of researchers from American and European institutions reveal that Piezo1, a lesser-understood protein, acts as a “brake” system, helping blood flow return to normal after neural activity..."

The association of leptin and incident hypertension in the reasons for geographic and racial differences in stroke (REGARDS) cohort

Posted October 23, 2024

"Leptin is an adipokine associated with obesity and with hypertension in animal models. Whether leptin is associated with hypertension independent of obesity is unclear. Relative to White adults, Black adults have higher circulating leptin concentration..."

Assessing prenatal and early childhood social and environmental determinants of health in the HEALthy Brain and Child Development Study (HBCD)

Posted October 23, 2024

"The HEALthy Brain and Child Development (HBCD) Study, a multi-site prospective longitudinal cohort study, will examine human brain, cognitive, behavioral, social, and emotional development beginning prenatally and planned through early childhood..."

Health Watch: UVM researchers unlock secrets of brain blood flow in cognitive health

Posted October 16, 2024

"Osama Harraz, Ph.D and his team of researchers at the University of Vermont’s Larner College of Medicine have made a breakthrough that could help in the effort to better understand the causes of dementia and how to stop it..."